Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 17
CJC-1295 With DAC vs Without DAC
CJC-1295 with DAC and without DAC are chemically different molecules with different half-lives, not two doses of the same peptide.
Photos vs Self-Report: GLP-1 Accuracy
A University of Michigan study compared medication photos against self-reports for 322 GLP-1 users and found real gaps in compounded-drug reporting.
Medicare's GLP-1 Bridge, By the Numbers
Eli Lilly says its drugs cover 70% of the 700,000 Medicare patients who started a GLP-1 since the temporary Bridge program opened in July 2026.
Novo Nordisk CEO open to NYSE upgrade
Novo Nordisk's CEO says a direct NYSE listing has advantages, a shift tied to Ozempic and Wegovy's US sales base and future R&D funding.
5mg vs 10mg Vials: What's Actually Missing
CJC-1295 and ipamorelin vial size doesn't decide potency. What's actually missing is any FDA-recognized reconstitution or stability standard for either peptide.
Semaglutide mechanism: the missing pieces
Semaglutide binds a well-mapped receptor, but a 2026 SELECT trial analysis shows weight loss explains only part of its heart benefit.
Semaglutide and Podocyte Senescence
Semaglutide cuts kidney disease events in trials. Researchers now ask whether slowing podocyte senescence in kidney filter cells explains part of why.
What explains semaglutide's heart benefit?
A SELECT trial mediation analysis finds weight, waist size and inflammation changes explain only a third of semaglutide's 20% cardiovascular risk reduction.
Semaglutide vs Older Diabetes Drugs
Semaglutide beats DPP-4 inhibitors like sitagliptin in trials, but head-to-head data against sulfonylureas and thiazolidinediones is thin.
Eating disorders in the GLP-1 era
GLP-1 drugs cut binge eating in trials and raise dietary restraint. Here is what clinicians are flagging on eating disorder risk, and what is unmeasured.
GIP receptors and brain dopamine in mice
A 2026 mouse study found GIP receptors in the lateral septum, where GIP and GLP-1 agonists cut electrically evoked dopamine release.
GLP-1 Prescribing Without an Indication
A US records study of 92 million adults found GLP-1 prescribing without a documented indication rose 15-fold, and 35.1% of recipients had a normal BMI.